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During the first trimester of pregnancy, the uterine
spiral arteries are remodeled, creating heavily dilated
conduits that lack maternal vasomotor control but
allow the placenta to meet an increasing requirement
for nutrients and oxygen. To effect permanent vaso-
dilatation, the internal elastic lamina and medial elas-
tin fibers must be degraded. In this study, we sought
to identify the elastolytic proteases involved in this
process. Primary first-trimester cytotrophoblasts
(CTBs) derived from the placenta exhibited intracel-
lular and membrane-associated elastase activity;
membrane-associated activity was primarily attribut-
able to matrix metalloproteinases (MMP). Indeed,
Affymetrix microarray analysis and immunocyto-
chemistry implicated MMP-12 (macrophage met-
alloelastase) as a key mediator of elastolysis. Cultured
human aortic smooth muscle cells (HASMCs) exhib-
ited constitutive membrane-associated elastase activ-
ity and inducible intracellular elastase activity; these
cells also expressed MMP-12 protein. Moreover, a spe-
cific inhibitor of MMP-12 significantly reduced CTB-
and HASMC-mediated elastolysis in vitro , to 31.7 
10.9% and 23.3  8.7% of control levels, respectively.
MMP-12 is expressed by both interstitial and endovas-
cular trophoblasts in the first-trimester placental bed
and by vascular SMCs (VSMCs) in remodeling spiral
arteries. Perfusion of isolated spiral artery segments
with CTB-conditioned medium stimulated MMP-12 ex-
pression in medial VSMCs. Our data support a model
in which trophoblasts and VSMCs use MMP-12 coop-
eratively to degrade elastin during vascular remodel-
ing in pregnancy, with the localized release of elastin
peptides and CTB-derived factors amplifying elastin
catabolism. (Am J Pathol 2010, 177:2103–2115; DOI:
10.2353/ajpath.2010.100182)
Transformation of the uterine spiral arteries during the
first 20 weeks of gestation ensures that a constant supply
of blood is delivered to the developing placenta, at an
optimal rate of flow.1–3 This allows the placenta to meet
an increasing requirement for nutrients and oxygen and
enables the developing fetus to attain its growth potential.
The remodeling process leads to vessel dilatation, loss of
spirality, and decreased vasoactivity, allowing a nonpul-
satile low-pressure supply of blood to be delivered to
placental villi at the maternofetal interface. Early alter-
ations in arterial structure include endothelial vacuolation,
hypertrophy of vascular smooth muscle cells (VSMCs),
and disruption of medial smooth muscle layers, which
occur in the absence of fetal-derived trophoblast and
correlate with perivascular accumulation of macro-
phages and uterine natural killer (uNK) cells.4,5 After
colonization of the uterine decidua and myometrium by
extravillous cytotrophoblast (EVT), endothelial cells and
VSMCs are lost from the arterial wall and replaced by
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trophoblast embedded in a fibrinoid matrix. Remodeling
is regulated in a spatial and temporal manner, such that
the successive steps of trophoblast adherence, intrava-
sation, fibrinoid deposition, and mural incorporation are
effected without any loss in vessel integrity. A complex
and highly orchestrated combination of vascular cell ap-
optosis, dedifferentiation, and matrix breakdown is prob-
ably required to achieve this alteration in vessel wall
structure.5–9
Two distinct populations of EVT originate from anchor-
ing placental villi and contribute to vessel transforma-
tion.10,11 Interstitial EVT invade the uterine wall, migrating
through the decidua and myometrium to adopt a perivas-
cular position. Endovascular EVT enter the lumen of the
spiral arteries and migrate as far as the first third of the
myometrium, colonizing the arterial wall from within. Im-
paired arterial remodeling is distinguished by shallow
EVT invasion, decreased numbers of EVT, and the per-
sistence of muscular, narrow-bore arteries, and is asso-
ciated with second trimester miscarriage,12 preterm la-
bor,13 pre-eclampsia,14 and fetal growth restriction.15
To effect a permanent increase in vessel diameter it is
crucial that elastin fibers within each artery are catabo-
lized, eliminating their capacity for stretch and recoil.
Myometrial segments of the spiral arteries possess an
internal elastic lamina (IEL), and the musculo-elastic me-
dia of both decidual and myometrial arteries is rich in
elastic fibers.16,17 During pregnancy, EVT traverse the
IEL during mural incorporation,18 thus it is highly likely
that they possess elastase activity: indeed, first-trimester
EVT synthesize and secrete the elastolytic proteases ma-
trix metalloproteinase-2 (MMP-2), MMP-7, MMP-9, ca-
thepsin B, and cathepsin L.19,20 Although both uNK cells
and macrophages produce enzymes capable of elastoly-
sis,5 uNK cells are not abundant in myometrium,21 and
elastin breakdown is associated with the presence of
endovascular EVT17 rather than macrophages.22 Previ-
ous studies have demonstrated that the availability of
nitric oxide (NO) can influence protease expression and
activity,23–26 and we have shown NO to be an important
regulator of trophoblast function.27–29 As dysregulation of
NO production has been implicated in the pathogenesis
of pre-eclampsia and intrauterine growth restriction
(IUGR),30–32 NO availability may regulate the process of
arterial remodeling by controlling trophoblast elastolysis.
Rodent models of atherosclerosis have highlighted a
role for VSMC-derived cathepsins as mediators of IEL
breakdown during lesion formation,33 demonstrating that
the arterial wall may be a potential source of elastases.
Similarly, caspase-2, -3, and -7 derived from apoptotic
VSMCs have been implicated as mediators of elastin
breakdown.34 Thus, during the process of spiral artery
transformation, resident VSMCs may also be stimulated
to produce elastase(s) in response to pregnancy hor-
mones, trophoblast invasion, or soluble factors released
by cells within the placental bed. In this study we have
investigated the origin and identity of the proteases in-
volved in mediating elastin breakdown during spiral ar-
tery remodeling.
Materials and Methods
Reagents
Caspase inhibitor zVAD-fmk and cathepsin inhibitor Z-
Phe-Gly-NHO-Bz-pOMe were from Calbiochem (San Di-
ego, CA); MMP inhibitor N-Isobutyl-N-(4-methoxyphenyl-
sulfonyl)-glycyl hydroxamic acid (NNGH) was from
Biomol International (Exeter, UK); urokinase plasminogen
activator (uPA) inhibitor uPA-STOP was from American
Diagnostica Inc. (Stamford, CT); in situ cell death detec-
tion kit (TUNEL) was from Roche (Lewes, UK); Cell-
Tracker CM-Dil was from Molecular Probes (distributed
by Invitrogen Ltd, Paisley, UK); recombinant human
TRAIL was from PeproTech (London, UK); inducible NOS
(iNOS) inhibitor 1400W was from Axxora (Nottingham,
UK); porcine pancreatic elastase, N-succinyl-(L-ala-
nine)3-p-nitroanilide, elastin from bovine neck ligament,
Congo-Red labeled elastin, N-Nitro-L-arginine methyl
ester hydrochloride (L-NAME hydrochloride), phenyl-
methanesulfonyl fluoride (PMSF) were from Sigma-Al-
drich (Poole, UK); tissue culture medium, glutamine, an-
tibiotics were from Cambrex (Wokingham, UK); fetal
bovine serum (FBS) was from Gibco (distributed by In-
vitrogen Ltd, Paisley, UK); OCT embedding medium was
from Raymond A. Lamb (London, UK); Matrigel was from
BD Discovery Labware (Bedford, MA); mouse anti-hu-
man cytokeratin-7 monoclonal antibody (clone OV-TL 12/
30), mouse anti-human -smooth muscle actin monoclo-
nal antibody (clone 1A4), mouse anti-human CD31
monoclonal antibody, universal negative control IgG
(IgG1, IgG2a, IgG2b, IgG3, and IgM; 20 g/ml of each
isotype, 100 g/ml total concentration), biotinylated rab-
bit anti-mouse, goat anti-mouse and swine anti-rabbit
secondary antibodies, streptavidin-FITC were from Dako
(Glostrup, Denmark); mouse anti-human MMP-12 mono-
clonal antibody (catalytic domain) was from R&D Sys-
tems (Minneapolis, MN); rabbit anti-human MMP-12
monoclonal antibody (carboxyterminal; EP1261Y) and
mouse anti-human HLA-G monoclonal antibody were
from Abcam (Cambridge, UK); Vectashield mounting me-
dium was from Vector Laboratories Inc. (Burlingame,
CA); Elastolux intracellular elastase activity assay was
from OncoImmunin (Gaithersburg, MD). U133A/B Gene-
Chips were obtained from Affymetrix (Affymetrix Inc.,
Santa Clara, CA). Labeling reagents for GeneChips were
purchased from Enzo Life Sciences (Enzo, Farmingdale,
NY). The specific MMP-12 inhibitor 470.1 (Ki 0.19 nmol/L;
purity 98%) was kindly donated by Dr. V. Dive (Com-
pound 1 in Ref. 35).
Cell Culture
Primary cytotrophoblasts (CTBs) were isolated as previ-
ously described36 and were cultured in a 1:1 ratio DMEM:
Ham’s F12 medium supplemented with FBS (10%),
glutamine (2 mmol/L), penicillin (100 units/ml), and
streptomycin (0.1 mg/ml). CTBs were grown on Matrigel-
coated flasks (diluted 1:10 in serum-free medium) to
promote a more advanced extravillous phenotype. Cells
were also seeded onto Matrigel-coated coverslips and
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cultured for 48 hours for immunostaining. After 48 hours
in culture, 91.1  4.2% (n  5) of cells were immunopo-
sitive for cytokeratin-7. Cells were also positive for
HLA-G. To prepare CTB-conditioned medium, 1.5  106
CTBs were seeded into a Matrigel-coated T25 flask and
left for 3 hours to adhere. The medium was removed, the
cells were washed with PBS, and 5 ml of fresh serum-
free DMEM/F12 was added to the flask. After 48 hours
the medium was removed, centrifuged to eliminate cell
debris, and stored at 20°C. The mean protein con-
centration of the CTB-conditioned medium was
193.45  5.6 g/ml (n  8). Conditioned medium was
diluted 1:1 with unconditioned medium before use.
Human aortic SMCs (HASMCs) were cultured in
Kaighn’s modification of Ham’s F12 medium and
SGHPL-4 cells were cultured in Ham’s F10 medium. Me-
dia was supplemented with FBS (10%), glutamine (2
mmol/L), penicillin (100 units/ml), and streptomycin (0.1
mg/ml). To generate HASMC- and SGHPL-4-conditioned
medium, 0.5  106 cells were seeded into a T25 flask.
After 24 hours the medium was removed, centrifuged to
eliminate cell debris, and stored at 20°C. The mean
protein concentrations of the HASMC- and SGHPL-4–
conditioned media were 244.36 10.0 g/ml (n 8) and
261.31  6.7 g/ml (n  6), respectively. Conditioned
medium was diluted 1:1 with unconditioned medium be-
fore use.
Tissue
Informed consent was obtained for all myometrial and
placental tissue used in this study, and local ethics com-
mittee approval was in place. First-trimester placenta
(n  21) and decidua (n  8; 7–12 weeks gestation) was
obtained after surgical or medical termination of preg-
nancy for psychosocial reasons. Term decidual/myome-
trial biopsies (n  6) taken from non-placental bed tissue
were obtained from women with normal pregnancies at
elective caesarean section.
Vessel Explant Model
Dissection and perfusion of spiral arteries was performed
as previously described.36 Non-placental bed decidual/
myometrial biopsies were obtained at Caesarean section
from healthy pregnant women at term. Unmodified spiral
arteries were dissected under sterile conditions and
mounted on glass cannulae in a pressure myography
perfusion chamber (Living Systems Instrumentation, Bur-
lington, VT). A subset of vessels were fixed immediately,
and the remaining arteries were denuded of endothelium
by passing a column of air through the lumen; removal of
the endothelium was confirmed by CD31 immunostain-
ing. Denuded arteries were perfused with unconditioned
CTB-medium (1:1 DMEM:Ham’s F12; control) or CTB-
conditioned medium (diluted 1:1 with unconditioned
DMEM:Ham’s F12). The ends of each vessel were tied off
to prevent the medium from leaking out, and the arteries
were cultured in 1:1 DMEM:Ham’s F12 culture medium
for 24 hours.
Immunocytochemistry
Arteries were fixed (2% [vol/vol] paraformaldehyde in
PBS, 30 minutes) and incubated with sucrose (0.5 mol/L
in PBS; 1 hour). Tissue was embedded in OCT, frozen,
and cut into 10-m transverse sections. For immunostain-
ing of VSMCs, cells were cultured on glass coverslips.
Cells/tissue sections were fixed (4% [vol/vol] paraformal-
dehyde in PBS; 20 minutes), permeabilized (0.1% [vol/
vol] Triton-X in PBS; 5 minutes), and washed in PBS.
Antibodies were applied for 1 hour, and slides were
washed (3  5 minutes; PBS) after each antibody incu-
bation. Working concentrations of antibodies were as
follows: cytokeratin-7 (0.9 g/ml), CD31 (5.15 g/ml),
MMP-12 (catalytic domain; 10 g/ml), biotinylated goat
anti-mouse (7 g/ml), and swine anti-rabbit secondary
antibodies (4.05 g/ml), streptavidin-FITC (10 g/ml),
control IgG (20 g/ml of each isotype, 100 g/ml final
concentration). Sections and coverslips were mounted
using Vectashield mounting medium containing pro-
pidium iodide or DAPI and imaged using either an Olym-
pus IX70 inverted fluorescence microscope or a Biorad
Radiance 2100 confocal microscope with a10 or a40
oil immersion objective lens and LaserSharp 2000 image
analysis software.
Immunohistochemistry
Wax-embedded decidual tissue sections (5 m) were
deparaffinized in Histoclear and alcohol and micro-
waved for 10 minutes in sodium citrate buffer (0.01
mol/L; containing 0.05% [vol/vol] Tween 20, pH 6.0) to
facilitate antigen unmasking. After cooling, endoge-
nous peroxide activity was blocked by placing the
slides in methanol containing 0.4% (vol/vol) HCl and
0.5% (vol/vol) hydrogen peroxide for 30 minutes. Tis-
sue sections were washed three times in 0.05 mol/L
Tris buffered saline (TBS) and blocked with 5% (wt/vol)
BSA in TBS for 30 minutes. Primary antibodies, diluted
to working concentration with 0.05 mol/L TBS (cytoker-
atin-7, 0.9 g/ml; MMP-12 [carboxyterminal], 4 g/ml;
HLA-G, 2 g/ml; -smooth muscle actin, 0.18 g/ml;
control IgG [20 g/ml of each isotype, final concentra-
tion 100 g/m]) were applied to the tissue sections,
which were incubated overnight at 4°C in a humidity
chamber. Slides were washed (3 TBS), and the sec-
ondary antibodies, diluted in TBS (biotinylated swine
anti-rabbit IgG, 4.05 g/ml; biotinylated goat anti-
mouse IgG, 7 g/ml), were applied for 30 minutes at
room temperature. Slides were washed again (3 TBS)
and incubated with avidin peroxidase (5 g/ml in
0.125M TBS) for 30 minutes at room temperature.
Slides were washed in TBS and incubated for 1–5
minutes with 0.05% (wt/vol) DAB and 0.015% (vol/vol)
hydrogen peroxide. Slides were washed in dH2O,
counterstained with hematoxylin, rehydrated in alcohol
and Histoclear, and mounted in DPX mountant contain-
ing distyrene, a plasticizer, and xylene.
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Intracellular Elastase Activity Assay
Intracellular elastase activity was quantified using an
Elastolux assay kit. Cells were cultured alone or with
protease inhibitors as described. After trypsinization, cell
pellets were incubated in culture medium containing a
cell-permeable elastase substrate (9 mol/L) and 10%
FBS, for 1 hour at 37°C. On cleavage by intracellular
elastases, the substrate becomes fluorescent and is re-
tained within the cell. Cells were washed once in PBS,
and the percentage of fluorescent cells was quantified
using a Coulter Epics Elite flow cytometer.
Total Elastase Activity Assay
Cell extracts were generated by incubating CTBs,
SGHPL-4, or HASMCs with 0.1% (vol/vol) Triton X100 in
PBS for 30 minutes. This process induced cell lysis,
release of intracellular elastases, and dissociation of
membrane-associated elastases. Extracts were centri-
fuged to remove any cellular debris, and the resulting
supernatant, which contained both intracellular and
membrane-associated elastases, was retained for analy-
sis. No elastase activity was detected in the cell pellets.
Supernatants or conditioned culture medium (50 l) were
incubated with 200 l of N-succinyl-(L-alanine)3-p-nitroa-
nilide (1 mmol/L) dissolved in Tris-HCl (200 mmol/L; pH
8.0) for 2 hours at 37°C in a 96-well plate. On cleavage by
elastase this substrate absorbs at 405 nm. After addition
of 5 l of glacial acetic acid, the A405 of each sample
was determined and compared to a calibration curve
prepared using porcine pancreatic elastase. The protein
concentration of each sample was measured using a
Biorad protein assay with a standard curve prepared
using bovine serum albumin. Elastase activity data were
expressed as activity per mg of protein.
Time Lapse Microscopy
Proliferating SGHPL-4 and HASMCs (0.25  106 cells)
were seeded into six-well plates and left to adhere. After
addition of elastin (1 mg/ml), NNGH (50 mol/L), and
L-NAME (5 mmol/L), elastin uptake was monitored by
time-lapse microscopy using an Olympus IX70 inverted
fluorescence microscope with a motorized stage and
cooled CCD camera (Hamamatsu model C4742–95) en-
closed in a humidified chamber at 37°C with 5% CO2 in
air, as described previously.37 Images were taken at
15-minute intervals, and time-lapse sequences were an-
alyzed using ImagePro Plus (Media Cybernetics, Silver
Spring, MD). Fifteen cells were scored from each field of
view (wells were analyzed in triplicate), and the time at
which a cell took up a fragment of elastin was recorded.
RNA Extraction, cRNA Synthesis, and Gene
Expression Profiling
EVT outgrowths from villous explants cultured on Matrigel
(obtained from six different first-trimester placentas, 7–10
weeks gestation) were isolated and total RNA was ex-
tracted as previously described.38,39 RNA integrity was
checked by agarose gel electrophoresis and with the
Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.,
Palo Alto, CA). Total RNA (5 g) was then used for
GeneChip analysis. Preparation of cRNA, hybridization to
human U133 GeneChips, and scanning of the arrays
were performed according to the manufacturer’s proto-
cols (Affymetrix Inc., Santa Clara, CA), as previously
described.40
Statistics
Statistical analyses were performed using GraphPad
Prism software version 4 (GraphPad Software, San Di-
ego, CA). Nonparametric data were represented by me-
dian and range and was analyzed using a Kruskal–Wallis
tests with appropriate post hoc analysis. Data represent
at least three independent experiments. Significance was
taken as P  0.05.
Results
Elastase Activity in Trophoblasts Is Attributed to
Caspases and Matrix Metalloproteinases
To investigate the contribution of trophoblast-derived
elastases to arterial remodeling, we analyzed intracellular
and total elastase activity of human first-trimester CTBs.
When cultured with Congo red-labeled elastin, CTBs
were observed to engulf and degrade elastin fibers (Fig-
ure 1A). CTBs exhibited detectable intracellular elastase
activity, which was significantly reduced by a broad
spectrum caspase inhibitor, but only when CTBs were
isolated from placentas of less than 9 weeks of gestation
(P  0.05; Figure 1B). None of the broad spectrum pro-
tease inhibitors tested reduced the intracellular elastase
activity of CTBs at later gestations, when added individ-
ually, or in combination (Figure 1C). Cell supernatants
containing both cytoplasmic and membrane-associated
proteases were prepared by incubating CTBs (8–10
weeks gestation) or the first-trimester extravillous tropho-
blast cell line SGHPL-4 with 0.1% (vol/vol) Triton X-100.
Supernatants were incubated with the elastase substrate
N-succinyl-(L-alanine)3-p-nitroanilide to quantify elastase
activity. Both SGHPL-4 cells and CTB supernatants dem-
onstrated marked elastase activity, which was completely
inhibited by the broad spectrum MMP inhibitor NNGH
(P  0.05, Figure 1, D and E). As the MMP inhibitor had
no effect on intracellular elastase activity, the MMP activ-
ity in the CTB supernatants must be attributable to mem-
brane-associated elastases. Elastase activity in CTB-
conditioned medium was below the level of detection of
this assay (data not shown).
To investigate the kinetics of elastin breakdown,
SGHPL-4 cells were incubated with elastin and monitored
at 15-minute intervals for 24 hours by time-lapse video
microscopy. Over time, cells began to engulf and de-
grade these fibers, retaining small pieces of elastin within
their cytoplasm (Figure 2A). After 24 hours, approxi-
mately 85% of control cells contained one or more elastin
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fragments (Figure 2B). Addition of the broad-spectrum
MMP inhibitor zVAD-fmk to the cultures significantly re-
duced the percentage of SGHPL-4 cells containing elas-
tin to 66% of controls after 6 hours and 81% after 24 hours
(P  0.05; Figure 2C). It has previously been shown that
in some cell types, the availability of NO can influence the
expression and activity of certain proteases,23–26 and we
have previously identified MMP-9 as a potential target for
S-nitrosylation in trophoblast.29 Thus, we investigated
whether elastin uptake was NO-dependent, using the
nitric oxide synthase (NOS) inhibitor L-NAME. In the pres-
ence of L-NAME, the percentage of cells containing elas-
tin fragments was significantly reduced after 6 hours (P
0.01) but not at any other time points, implying that NO
availability is not a prerequisite for elastin uptake.
Identification of Candidate Elastases in
First-Trimester Trophoblasts
To determine the identity of candidate trophoblast elas-
tases, a transcriptomic approach was used. Affymetrix
gene chip analysis of two separate pools of first-trimester
EVT mRNA (7–10 weeks gestation) demonstrated that
caspase-2, MMP-2, and MMP-12 were the most highly
expressed protease transcripts (Table 1). The role of
MMP-2 in migration and invasion of first-trimester EVT has
been well characterized previously20; however, the role
of MMP-12 (macrophage metalloelastase) in trophoblast
function has not been investigated.
MMP-12 Mediates Elastolysis in First-Trimester
Trophoblasts
To validate our transcriptomic data, isolated first-trimes-
ter CTBs were immunostained with an antibody to MMP-
12, confirming protein expression (Figure 3, A and B). As
previously shown, pretreatment of individual CTB super-
natants (7–12 weeks gestation) with a broad-spectrum
MMP inhibitor abolished elastase activity (P  0.001;
Figure 3C). Pretreatment of the same supernatants with a
specific inhibitor of MMP-12 (470.1) significantly reduced
elastase activity to a mean value of 31.7  10.9% (P 
0.05) of control activity, implicating MMP-12 as an impor-
tant membrane-associated elastase in trophoblast.
Intracellular Elastase Activity of HASMCs Is
Stimulated by Elastin Fragments
As VSMC-derived elastases have been shown to me-
diate elastin breakdown during the progression of ath-
erosclerosis and aneurysm, we investigated whether
VSMCs could contribute to the elastolysis observed
during arterial remodeling in pregnancy. Only a small
Figure 1. Elastase activity in first-trimester cytotrophoblasts. A: First-trimester cytotrophoblasts (CTBs) were cultured with Congo Red-labeled elastin (1 mg/ml)
for 48 hours and stained with an antibody to cytokeratin-7 (green). Serial images at 2-m intervals along the z axis were captured by confocal microscopy; inset
depicts intracellular elastin fragments. Scale bars  50 m (n  3). B: CTBs were isolated from placentas of fewer than 9 weeks gestation or greater than 9-weeks
gestation. Cells were cultured with a vehicle control (DMSO), the broad-spectrum caspase inhibitor zVADfmk (50 mol/L), the broad-spectrum MMP inhibitor
NNGH (50 mol/L), the broad-spectrum cathepsin inhibitor Z-FG-NHO-BzOMe (10 mol/L), or (C) with all three inhibitors for 18 hours. B and C: Intracellular
elastase activity was determined using a cell-permeable elastase substrate. Median  range (n  3). B: *P  0.05; Kruskal-Wallis test. D and E: Membrane-
associated elastase activity in SGHPL4 (D) and first-trimester CTBs (E) was assessed using the substrate N-succinyl-(L-alanine)3-p-nitroanilide. Cell supernatants
were assayed for elastase activity in the presence of vehicle control (DMSO), zVADfmk (50 mol/L), NNGH (50 mol/L), Z-FG-NHO-BzOMe (10 mol/L), or the
uPA inhibitor uPA-STOP (10 mol/L). Median, (n  3); *P  0.05; Kruskal-Wallis test.
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proportion of cultured HASMCs exhibited exogenous
intracellular elastase activity (4.81%  1.4; n  7); this
was unchanged after culture on Matrigel, a collagen IV
and laminin-rich extracellular matrix preparation similar
in composition to the basement membrane on which
VSMCs reside in vivo (Figure 4A). Similarly, HASMCs
cultured with CTB-conditioned medium did not exhibit
increased elastase activity, suggesting that soluble
factors released from trophoblast do not modulate in-
tracellular elastase activity in vitro. As VSMCs may be
exposed to elastin fragments generated by tropho-
blast-mediated elastolysis during remodeling in vivo,
HASMCs were cultured with elastin fibers. This treat-
ment significantly enhanced intracellular elastase ac-
tivity (P  0.05), suggesting that the presence of elas-
tin fragments in vivo may stimulate elastase production
in the arterial wall.
Figure 2. Elastin uptake and MMP expression in first-trimester trophoblasts.
SGHPL-4 were cultured with elastin fragments (1 mg/ml) (closed diamonds)
in the presence of vehicle control (DMSO), the broad-spectrum MMP inhib-
itor NNGH (50 mol/L; closed triangles), or L-NAME (5 mmol/L; open
squares) for 24 hours. Cultures were monitored by time-lapse video-micros-
copy, and the time point at which an elastin fragment appeared within a cell
was recorded; 45 cells were scored for each treatment. A: Selected images
taken at hourly intervals, showing accumulation of elastin fragments within
a cell. Arrows denote elastin fragments. Scale bar  10 m. B: Time course
of elastin uptake. Mean  SEM (n  4). C: Percentage of SGHPL-4–contain-
ing elastin fragments at 6, 12, and 24 hours. Black bars represent control cells,
gray bars represent NNGH-treated cells, and white bars represent L-NAME–
treated cells. Median  range (n  4); *P  0.05, **P  0.01; two-way
analysis of variance.
Table 1. Affymetrix Analysis of Protease Expression in First
Trimester EVT
Protease
Affymetrix
reference
number
Relative
expression 1
Relative
expression 2
MMP-2 201069_at 19,976.2* 25,128.7*
MMP-3 205828_at 793.2 1557.3
MMP-9 203936_s_at 193.3 258.7
MMP-11 203878_s_at 1330.8 1031
MMP-12 204580_at 18,953.8* 33,777.5*
MMP-14 160020_at 980 859.1
MMP-15 203365_s_at 6427 2102.7
MMP-19 204575_s_at 1151.6 950.2
Caspase-1 211366_x_at 129.4 244.9
Caspase-2 226032_at 4885.5* 5775.1*
Caspase-3 202763_at 467.8 352.6
Caspase-4 209310_s_at 370.7 406.5
Caspase-4 213596_at 58.5 143.1
Caspase-6 209790_s_at 382.7 250.3
Caspase-6 211464_x_at 210.4 203.6
Caspase-7 207181_s_at 801.6 797
Caspase-8 213373_s_at 167.8 210.8
Caspase-9 203984_s_at 490.6 449.2
Relative expression of protease transcripts in two pools of first trimester
EVT mRNA. Asterisks denote the most highly expressed transcripts.
Figure 3. Membrane-associated MMP-12 mediates elastolysis in first-trimes-
ter CTBs. First-trimester CTBs cultured for 48 hours on Matrigel-coated
coverslips were immunostained with control IgG (A) or an antibody to
MMP-12 (B) (catalytic domain; green); nuclei were counterstained with
propidium iodide (red). Scale bar  50 m. Pictures are representative of
three independent CTB isolations. C: Membrane-associated elastase activity
in first-trimester CTBs was assessed using the substrate N-succinyl-(L-ala-
nine)3-p-nitroanilide. Cell supernatants were assayed for elastase activity in
the presence of vehicle control (DMSO), the broad-spectrum MMP inhibitor
NNGH (50 mol/L), or the specific MMP-12 inhibitor 470.1 (100 mol/L).
Median, (n  6); *P  0.05; ***P  0.001; Kruskal–Wallis test.
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Intracellular Elastase Activity of HASMCs Is
Partially Mediated by Serine Proteases
To identify the intracellular proteases responsible for the
observed elastase activity, while minimizing the amount
of elastin introduced into the flow cytometer, HASMCs
were cultured on elastin-coated plates for 48 hours and
incubated with cell-permeable protease inhibitors for a
further 6 hours. Broad-spectrum caspase, MMP, and ca-
thepsin inhibitors had no effect on intracellular elastase
activity (Figure 4B); however, the serine protease in-
hibitor PMSF reduced activity by approximately 35%
(P  0.05; Figure 4C). Pretreatment of HASMCs with
the broad-spectrum NOS inhibitor L-NAME or the spe-
cific iNOS inhibitor 1400W for 24 hours had no effect on
intracellular elastase activity, suggesting that it was not
NO-dependent.
Membrane-Associated Elastase Activity in
HASMCs Is MMP-Dependent
To identify membrane-associated, pericellular, or se-
creted elastases, HASMC supernatants or conditioned
medium were incubated with N-succinyl-(L-alanine)3-
p-nitroanilide. HASMCs cultured on plastic exhibited
constitutive membrane-associated elastase activity,
which was completely inhibited by a broad spectrum
MMP inhibitor (P  0.01; Figure 4D). HASMCs cultured
on plates coated with elastin did not exhibit an en-
hancement of elastase activity (0.435  0.16 g elas-
tase/mg protein [plastic] versus 0.316  0.09 g elas-
tase/mg protein [elastin], mean  SEM; n  4) and
again, activity was completely inhibited by a broad
spectrum MMP inhibitor (P  0.05). The broad spec-
trum caspase inhibitor zVADfmk, the cathepsin inhibi-
Figure 4. HASMCs exhibit elastase activity at-
tributable to serine proteases and MMP. A:
HASMCs were cultured on uncoated plastic
dishes (control), Matrigel-coated dishes, or with
first-trimester CTB-conditioned medium (50%
[vol/vol]), or elastin fibers (1 mg/ml) for 48
hours. Intracellular elastase activity was quanti-
fied using a cell-permeable elastase substrate
and flow cytometry. Median (n  3); *P  0.05;
Kruskal-Wallis test. B: HASMCs were cultured
on plates coated with elastin fragments for 48
hours and were incubated with vehicle control
(DMSO), the broad-spectrum caspase inhibi-
tor zVADfmk (50 mol/L), the MMP inhibitor
NNGH (50 mol/L), or the cathepsin inhibitor
Z-FG-NHO-BzOMe (10 mol/L) for a further six
hours. Intracellular elastase activity was deter-
mined as above. Median (n  4). C: HASMCs
were cultured on elastin coated flasks for 48
hours then incubated with vehicle control
(DMSO), the serine protease inhibitor PMSF (10
mg/ml; 6 hours), the NOS inhibitor L-NAME (5
mmol/L; 24 hours), or the iNOS inhibitor 1400W
(5 mol/L; 24 hours). Intracellular elastase ac-
tivity was determined as above. Median (n 4);
*P  0.05; Kruskal-Wallis test. D and E: Mem-
brane-associated elastase activity in HASMCs
was assessed using the substrate N-succinyl-(L-
alanine)3-p-nitroanilide. Cell supernatants were
assayed for elastase activity in the presence of
vehicle control (DMSO), the caspase inhibitor
zVADfmk (50 mol/L), the MMP inhibitor
NNGH (50 mol/L), the uPA inhibitor uPA-
STOP (10 mol/L), or the cathepsin inhibitor
Z-FG-NHO-BzOMe (10 mol/L). D: HASMCs
were cultured in uncoated flasks (white bars) or
in flasks coated with elastin fragments (black
bars) for 48 hours. Median  range (n  4);
*P  0.05, **P  0.01; Kruskal–Wallis test. E:
HASMCs were cultured on elastin coated flasks,
in the absence or presence of the NOS inhibitor
L-NAME (5 mmol/L; 24 hours) or the iNOS in-
hibitor 1400W (5 mol/L; 24 hours). Control
supernatants were analyzed in the presence of
vehicle control (DMSO) or the serine protease
inhibitor PMSF (10 mg/ml). Median (n  4);
*P  0.05; Kruskal–Wallis test.
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tor Z-FG-NHO-BzOMe, and uPA-STOP had no effect.
As the MMP inhibitor had no effect on intracellular
elastase activity of HASMCs, the activity detected in
the cell supernatants must be attributable to mem-
brane-associated elastases. Elastase activity present
in the conditioned medium of HASMCs was below the
level of detection (data not shown).
Membrane-Associated Elastase Activity in
HASMCs Is NO-Dependent
To investigate whether the activity of elastolytic MMP was
NO-dependent, HASMCs were pretreated with L-NAME
or the iNOS inhibitor 1400W for 24 hours before prepa-
ration of cell supernatants. Elastase activity was signifi-
cantly decreased by both inhibitors, indicating that NO
availability is necessary for effective MMP function in
HASMCs (P  0.05; Figure 4E).
Elastin Uptake Is MMP- and NO-Dependent
To study elastin fragment uptake over time, HASMCs
were incubated with elastin and monitored by time lapse
video-microscopy (Figure 5A). When HASMCs were cul-
tured with elastin alone, approximately 80% of control
cells contained elastin fragments after 24 hours (Figure
5B). Addition of NNGH or L-NAME to the cultures had a
marked effect on the kinetics of elastin uptake. Uptake
was significantly decreased at 6 hours, 12 hours, and 24
hours in the presence of the MMP inhibitor (P 0.01, P
0.001), and at 6 hours and 12 hours by L-NAME (P 
0.05, P  0.001; Figure 5C). These data suggest that
MMP and NO are required for effective elastin uptake by
HASMCs.
VSMCs Express Elastolytic MMP in Vitro and
in Vivo
To investigate whether cultured HASMCs express MMP-
12, immunostaining was used to confirm expression of
the active form (Figure 6, A and B). During pregnancy,
invading EVT release soluble factors including FasL and
TRAIL, which trigger VSMC apoptosis.41,42 To assess
whether these factors can alter MMP-12 expression in
spiral artery VSMCs ex vivo, unremodeled spiral arteries
were dissected from myometrial biopsies obtained from
healthy pregnant women undergoing caesarean section
at term. Vessels were denuded of endothelium to facili-
tate access of factors to the underlying VSMCs then
perfused with unconditioned medium (control), CTB-con-
ditioned medium (which contains detectable soluble
FasL but not TRAIL),41,42 or recombinant human TRAIL
(rhTRAIL), and cultured for 24 hours. CD31 immunostain-
ing confirmed removal of the endothelium, while morpho-
logical analysis of the arterial wall verified the integrity of
the underlying VSMC layers (Figure 6, C and D). No
MMP-12 expression was observed in VSMCs of freshly
isolated arteries with intact endothelium (Figure 6E) or in
denuded vessels perfused with unconditioned (control)
medium (Figure 6F), indicating that removal of the en-
dothelium does not up-regulate MMP-12 expression in
the underlying VSMCs. Introduction of CTB-condi-
tioned medium or rhTRAIL into the lumen of denuded
arteries induced expression of active MMP-12 in
VSMCs, although the extent of expression was hetero-
geneous, with only 30% of tissue sections examined
containing MMP-12–positive cells (Figure 6, G and H).
These data suggest that factors produced by EVT dur-
ing colonization and remodeling of the spiral arteries
have the ability to influence MMP-12 expression in a
proportion of mural VSMCs. Membrane-associated
Figure 5. Elastin uptake in HASMCs is regulated by MMP and NO. HASMCs
were cultured with elastin fragments (1 mg/ml) in the presence of vehicle
control (DMSO), the broad-spectrum MMP inhibitor NNGH (50 mol/L), or
L-NAME (5 mmol/L) for 24 hours. Cultures were monitored by time-lapse
video-microscopy, and the time point at which an elastin fragment appeared
within a cell was recorded. Forty-five cells were scored for each treatment. A:
Selected images taken at hourly intervals, showing accumulation of elastin
fragments within a cell. Arrows denote elastin fragments. Scale bar 10 m.
B: Time course of elastin uptake. Mean  SEM (n  4). C: Percentage of
HASMC-containing elastin fragments at 6, 12, and 24 hours. Black bars
represent control cells, gray bars represent NNGH-treated cells, and white
bars represent L-NAME-treated cells. Median  range (n  4); *P  0.05,
**P  0.01, ***P  0.001; two-way analysis of variance.
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elastase activity of HASMCs was reduced to a mean
value of 23.3  8.7% of control activity after pretreat-
ment of HASMC supernatants with a specific inhibitor
of MMP-12 (P  0.05; Figure 6I). As previously ob-
served, the broad spectrum MMP inhibitor NNGH abol-
ished elastase activity (P  0.001). These data impli-
cate MMP-12 as an important mediator of HASMC
elastolysis in vitro.
MMP-12 Is Expressed by Trophoblast and
VSMCs in the First Trimester of Pregnancy
Sections of first-trimester placenta and decidua (8–12
weeks gestation) were stained with an antibody to
MMP-12; villous CTBs, trophoblast cell columns and
EVT were immunopositive (Figure 7, A, B, D, and E). A
subset of villous stromal cells, most likely placental
Figure 6. MMP-12 expression in cultured HASMCs and excised human spiral arties. A and B: Cultured HASMCs were immunostained with control IgG (A) or an
antibody to the catalytic domain of MMP-12 (B) (green). Nuclei were counterstained with propidium iodide (red). Scale bar  50 m. Intact human spiral arteries
(C) and arteries denuded of endothelium (D) were fixed immediately and stained with an antibody to CD31 (green). Nuclei were counterstained with propidium
iodide (red). Scale bar  100 m. C: Arrows denote endothelial cells. Note autofluorescence of elastin. E–H: Spiral arteries were denuded of endothelium and
were fixed immediately (E) or perfused with unconditioned first-trimester CTB medium (1:1 DMEM:Ham’s F12; control) (F), CTB-conditioned medium (diluted
1:1 with DMEM:Ham’s F12) (G), or rhTRAIL (0.5 g/ml in DMEM:Ham’s F12) (H) and cultured for 24 hours. Sections were stained with an antibody to the catalytic
domain of MMP-12 (green). Scale bar  100 m. Nuclei were counterstained with propidium iodide (red). Images are representative of six independent
experiments; however, MMP-12–positive VSMCs were only observed in seven or eight (	30%) of the 24 serial tissue sections examined from each vessel. I: HASMC
supernatants were assayed for membrane-associated elastase activity in the presence of vehicle control (DMSO), the broad-spectrum MMP inhibitor NNGH (50
mol/L), or the specific MMP-12 inhibitor 470.1 (100 mol/L). Median (n  6); *P  0.05; ***P  0.001; Kruskal–Wallis test.
Elastases and Spiral Artery Remodeling 2111
AJP October 2010, Vol. 177, No. 4
macrophages (Hofbauer cells), also expressed MMP-12
(Figure 7D). Medial VSMCs in unremodeled arteries
did not express MMP-12, consistent with our ex vivo
observations; however, decidual stromal cells were
weakly positive for MMP-12 and strong expression was
noted in the vascular endothelium (EC; Figure 7, C and
F). MMP-12 expression was also observed in endovas-
cular EVT (eEVT; identified by HLA-G immunostaining)
and heterogeneously in disrupted VSMCs (identified
by -smooth muscle actin immunostaining) in remod-
eling spiral arteries (Figure 7, G–L).
Discussion
Remodeling of uterine spiral arteries during pregnancy
involves not only replacement of vascular endothelial
cells and VSMCs by invading trophoblast but also struc-
tural and functional transformation of the vascular extra-
cellular matrix. To allow a permanent increase in luminal
diameter, the internal elastic lamina and medial elastin
fibers must be degraded. Matrix breakdown is mediated
in part by the actions of trophoblast-derived proteases,
and we now provide evidence that spiral artery VSMC-
Figure 7. MMP-12 expression in cultured VSMCs and excised human spiral arties. Serial sections of first-trimester placenta (n  5) and decidua basalis (n  8)
were immunostained with control IgG (A), an antibody to cytokeratin-7 (CK-7; B, C) or HLA-G (I) to detect trophoblasts, an antibody to -smooth muscle actin
(-SMA) to detect VSMCs (G and H), or an antibody to MMP-12 (carboxyl-terminal) (D–F, J–L). Sections were counterstained with hematoxylin. Scale bar  50
m. Serial sections: (A and D), (B and E), (C and F), (G and J), (H and K), (I and L). EC indicates endothelial cells; vCTB, villous cytotrophoblasts; VSMC, vascular
smooth muscle cell; eEVT, endovascular extravillous trophoblasts.
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derived proteases add their own contribution to elastin
catabolism.
Primary first-trimester CTBs can phagocytose elastin in
vitro and exhibit both intracellular and membrane-asso-
ciated elastase activity. Intracellular activity is partially
attributable to caspases in early gestation, but we were
unable to identify candidate enzymes beyond 9 weeks,
possibly due to functional redundancy of the enzymes
involved. Approximately 60–70% of membrane-associ-
ated elastase activity was attributable to MMP-12 (mac-
rophage metalloelastase), which is known to act in asso-
ciation with the cell surface43; it is likely that the remaining
proportion is mediated by a combination of MMP-2, -7,
and -9, which are capable of elastolysis and are ex-
pressed by first-trimester trophoblast.19,20 MMP-12 has
previously been implicated as a potential regulator of
trophoblast adhesion and migration44; here we identify
MMP-12 as a candidate elastase which is expressed by
both interstitial and endovascular trophoblasts in close
proximity to spiral arteries in first trimester. Although NO
bioavailability is an important regulator of trophoblast
function,27,28 including MMP-9 activity at the leading
edge of migrating cells,29 phagocytosis of elastin by
trophoblast was not reduced in the presence of a NOS
inhibitor.
Elastin degradation appears to be a cooperative pro-
cess, because VSMCs also have the capacity to engulf
and degrade small particles of elastin using intracellular
and membrane-associated enzymes. In vitro, HASMCs
expressed low endogenous levels of intracellular elas-
tase; however, this was significantly increased after cul-
ture with elastin and was mediated by serine proteases
independently of NO bioavailability. In contrast, HASMCs
exhibited constitutive membrane-associated elastase ac-
tivity, which was attributable to MMP and caspases, was
significantly reduced by broad-spectrum- and iNOS-spe-
cific inhibitors, and was not significantly increased after
culture with elastin. Phagocytosis of elastin fragments
was reduced in the presence of inhibitors of either MMP
or NOS. A major fraction of membrane-associated elas-
tase activity in VSMCs was attributable to MMP-12; more-
over, expression of MMP-12 was induced in the mural
VSMCs of excised spiral arteries that had been denuded
of endothelium and perfused with CTB-conditioned me-
dium. We therefore hypothesize that soluble factors se-
creted by endovascular EVT up-regulate MMP expres-
sion in spiral artery VSMCs in vivo, which contributes to, or
is a consequence of, the alteration in VSMC phenotype
observed in actively remodeling vessels.4,5 Indeed, the
hypertrophy, dedifferentiation, and disruption of medial
smooth muscle layers observed in vivo reflects transition
from a stable contractile phenotype toward a more syn-
thetic proliferative state, a change that has previously
been linked to enhanced MMP expression.45 Further-
more, cultured HASMCs constitutively expressed MMP-
12 in vitro, whereas medial VSMCs in excised spiral ar-
teries did not, and CTB-conditioned medium induced
MMP-12 expression in spiral artery VSMCs in situ but did
not enhance elastase activity of undifferentiated HASMCs
in vitro. These observations suggest that induction of
MMP-12 expression in VSMCs may be coincident with
dedifferentiation and loss of contractile phenotype. Our
finding that MMP-12 is expressed in layers of disrupted
VSMCs within remodeling arteries, but is absent from the
organized VSMC layers of unremodeled vessels, sup-
ports this hypothesis.
Breakdown of elastin and formation of elastin-derived
peptides (EDP) plays an important role in the regulation
of tissue remodeling. Macrophage-derived MMP-12 is
crucial for the development of emphysema in a murine
model46: release of chemotactic EDP recruits monocytes
to the lung, which differentiate into macrophages, gener-
ate more EDP, and perpetuate the condition. EDP also
stimulate chemotaxis and chemokinesis of leukocytes
into the walls of damaged arteries, where they contribute
to matrix breakdown and repair.47 It is therefore interest-
ing to note that leukocytes adopt a perivascular location
around untransformed vessels in the first-trimester pla-
cental bed48 and mediate the initial stages of vascular
transformation.5 EDP can also stimulate quiescent arterial
VSMCs to adopt a more proliferative phenotype49–52 and
promote MMP expression in cancer cell lines.53–55 In
addition, EDP may regulate NOS activity, as elastin pep-
tides stimulated NO production in coronary artery endo-
thelial cells and cardiomyocytes.56 Our data support a
model whereby trophoblast-mediated breakdown of the
elastin within the spiral arteries liberates EDP that pro-
mote MMP-12 expression in medial VSMCs. EDP may
also increase NO production and MMP activity in tro-
phoblasts, establishing a positive feedback mecha-
nism by which EDP production and MMP-12 activity are
maintained.
Elastase activity in HASMCs, but not CTBs, was de-
pendent on NO bioavailability. This is in contrast to pre-
vious work showing that NO donors stimulated MMP ex-
pression and activity in term CTBs, whereas NOS
inhibitors reduced it.57,58 These conflicting data may be
explained by the later gestational age of the cells, or
because we were studying elastolysis, rather than collag-
enolysis, which is primarily mediated by MMP-2 and -9.
Nitration of a tyrosine residue in active site of MMP-2 by
peroxynitrite59 or nitrosylation of a critical cysteine resi-
due in MMP-960 by NO and other reactive nitrogen oxides
has been shown to promote enzymatic activity. However,
cysteine residues in the zinc-tetrathiolate cluster of endo-
thelial NOS (eNOS) and iNOS are susceptible to NO-
induced thiol modification, leading to impaired stability of
NOS dimers.61–63 Hence, high concentrations of NO re-
sulting from forced expression of iNOS may reduce NOS
activity and therefore MMP activity. Cellular localization
could hold the key to successful MMP regulation by NO:
we and others have observed concentrated expression
of eNOS64 and iNOS29 in membrane ruffles at the leading
edge of migrating, but not static cells. Thus, localization
of NO production to the site of MMP activation may be
important in regulating enzyme activity, matrix break-
down, and cell migration.
In summary, we have identified a novel role for
MMP-12 as a mediator of uterine vascular remodeling
during pregnancy. Our data support a model whereby
trophoblast and vascular VSMCs use MMP-12 to coop-
eratively degrade mural elastin during spiral artery re-
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modeling, with the localized release of elastin peptides
and CTB-derived factors amplifying elastin catabolism.
The role of leukocytes in this scheme of events has yet to
be addressed; however, cytokines or chemokines re-
leased by decidual macrophages and uNK cells may
influence MMP-12 expression in VSMCs and EVT.44
Breakdown of elastin in decidual vessels may be initiated
by resident VSMCs before the arrival of the trophoblast,
facilitating the entry of both leukocytes and EVT into the
arterial wall. Macrophages and uNK cells may also con-
tribute to elastolysis in decidual arteries, via the release of
MMP-7 and MMP-9.5 However, MMP-12 expression and
elastolysis may not occur efficiently in the deeper myo-
metrial vessel segments until trophoblasts reside in close
proximity to the medial VSMCs. Interestingly, elastin ca-
tabolism is impaired in the myometrial spiral arteries of
women with pre-eclampsia,17 and a dramatic reduction
in expression of MMP-12 mRNA has been reported in the
first-trimester placentas of women who subsequently de-
velop pre-eclampsia,65 implicating MMP-12 as a poten-
tial therapeutic target. As MMP-12 is a multifunctional
enzyme that is capable of degrading not only elastin, but
collagen IV, laminin, fibronectin, heparan sulfate, and
vitronectin,66 there may be serious consequences if
MMP-12 expression is suboptimal. Pre-eclampsia is also
characterized by increased circulating concentrations of
the endogenous inhibitor of NOS asymmetric dimethyl
arginine (ADMA).30,32 It is therefore possible that this may
limit NO production, reduce elastase activity, and impair
arterial vasodilatation. However, further work is needed
to elucidate the complex mechanisms controlling ma-
trix breakdown and vascular transformation and to in-
vestigate the spatiotemporal interplay between medial
VSMCs, invasive trophoblast, and other cell types
present within the placental bed.
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